drugset / Trial / NCT00851227

Study to Compare Conivaptan in Subjects With Mild & Moderate Liver Impairment Versus Subjects With Normal Liver Function

NCT00851227

Phase 1 Completed 26 enrolled Cumberland Pharmaceuticals
Non-randomizedParallel-groupOpen-label

Summary

A study to compare a 48-hour continuous infusion of conivaptan in subjects with mild and moderate liver impairment versus subjects with normal liver function

Timeline

Start
2009-02
Primary completion
2010-01
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Conivaptan Small molecule Intravenous

Indications